Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Aluminum – calcium or magnesium element – or compound containing
Patent
1998-07-07
2000-03-28
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Aluminum, calcium or magnesium element, or compound containing
424702, 514249, 514419, 514458, 514474, 514929, A61K 31355, A61K 3134, A61K 3306, A61K 3304, A61K 31495, A61K 3150, A61K 3140
Patent
active
06042849&
ABSTRACT:
Magnesium is formulated in combination with vitamin E, vitamin C, folate, selenium, and optionally melatonin a unit dosage form for oral administration, for the treatment of vasoconstriction and the physiological and pathological conditions giving rise to vasoconstriction. These active agents complement each other in suppressing these conditions, using a variety of mechanisms operating in conjunction with one another. The inclusion of magnesium in a plurality of forms provides additional advantages in terms of controlling and sustaining the release of magnesium in locations along the digestive tract where the magnesium will have its greatest effectiveness as a therapeutic agent, thus improving control over the clinical bioavailability of magnesium and in improving the selection of appropriate therapeutic ranges.
REFERENCES:
B.M. Altura et al., "Magnesium in Cardiovascular Biology," Science and Medicine (Scientific American) (1995) 2(3): 28-37.
L.R. Barlow-Walden et al., "Melatonin Stimulates Brain Glutathione Peroxidase Activity," Neurochemistry International (1995) 26(5): 497-502.
F. Corica et al., "Effects of Oral Magnesium Supplementation of Plasma Lipid Concentrations in Patients with Non-Insulin-Dependent Diabetes Mellitus," Magnesium Research (1994) 7(1): 43-47.
J.J. Cunningham et al., "Vitamin C: An Aldose Reductase Inhibitor that Normalizes Erythrocyte Sorbitol in Insulin-Dependent Diabetes Mellitus," J. Am. Coll. Nutr. (1994) 13(4): 344-350.
J. Durlach et al., "Magnesium and Ageing. II. Clinical Data: Aethiological Mechanisms and Pathophysiological Consequences of Magnesium Deficit in the Elderly," Magnesium Research (1993) 6(4): 379-393.
J. Flammer, "To What Extent are Vascular Factors Involved in the Pathogenesis of Glaucoma?," Ocular Blood Flow (1995) 1: 13-39.
A.Z. Gaspar et al., "The Influence of Magnesium on Visual Field and Peripheral Vasospasm in Glaucoma," Ophthalmologica (1995) 209:11-13.
I.O. Haeffliger et al., "The Vascular Endothelium as a Regulator of the Ocular Circulation: A New Concept in Ophthalmology?," Survey of Ophthalmology (1994) 39(2): 123-132.
J. Ma et al., "Associations of Serum and Dietary Magnesium with Cardiovascular Disease, Hypertension, Diabetes, Insulin, and Carotid Arterial Wall Thickness: The ARIC Study," J Clin Epidermoil (1995) 48(7): 927-940.
A. Mezzetti et al., "Vitamins E, C and Lipid Peroxidation in Plasma and Arterial Tissue of Smokers and Non-Smokers," Atherosclerosis (1995) 112: 91-99.
C. Pieri et al., "Melatonin: A Peroxyl Radical Scavenger More Effective Than Vitamin E," Life Sciences (1994) 55(15): 271-276.
Y. Rayssiguier et al., "Magnesium and Ageing. I. Experimental Data: Importance of Oxidative Damage," Magnesium Research (1993) 6(4): 369-378.
R.J. Reiter et al., "A Review of the Evidence Supporting Melatonin's Role as an Antioxidant," J. Pineal Res (1995) 18:1-11.
G.T. Vatassery, "In Vitro Oxidation of Vitamins C and E, Cholesterol, and Thiols in Rat Brain Synaptosomes," Lipids (1995) 30(11): 1007-1013.
J. White Jr. et al., "Magnesium and Diabetes: A Review," The Annals of Pharmacotherapy (1993) 27: 775-780.
Facts and Comparisons, J.B. Lippincott Co., pp. 1-2a, 24, 33a, 1992.
CA 124:20800, Zidek, 1993.
CA 120:95292, Mirzoyan et al, 1993.
CA 96:51091, Yoon et al, 1981.
CA 71:100350, Kopjas, 1969.
CA 122:212713, Han et al, 1994.
Pearson Don C.
Richardson Kenneth T.
ChronoRX LLC
Jordan Kimberly
LandOfFree
Unit dosage forms for treatment of vasoconstriction and related does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Unit dosage forms for treatment of vasoconstriction and related , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Unit dosage forms for treatment of vasoconstriction and related will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1323858